Sanofi SA has reported data from a Phase 2 trial of a Janus Kinase 2 (JAK2) inhibitor in myelofibrosis which showed the therapy achieved reductions in spleen size and other disease symptoms in 31 randomised patients.
Another potential therapy for patients with melanoma has emerged with the disclosure on 6 December of preliminary results of a therapeutic cancer vaccine in which four patients showed an immune response. The vaccine has been developed by Scancell Holdings Plc.
The Roche Group is to coordinate a new project under the Innovative Medicines Initiative (IMI) under which 1,500 induced pluripotent stem (iPS) cell lines will be generated and characterised for use in the study of disease.
The management of Newron Pharmaceuticals S.p.A has overcome the opposition of a key shareholder and reached an agreement to acquire privately-held NeuroNova AB of Sweden in an all-share deal valued at €15.5 million.
Wilex AG has announced plans to reduce its Munich, Germany workforce by about 25% following the failure of its lead cancer product – an antibody for renal cell carcinoma – to meet its primary endpoint in a Phase 3 trial.
Is it possible to envisage a situation where drugs could be approved sooner by a regulatory authority, but for a more restricted use? And if so, would this be a way for pharmaceutical companies to get real-life data on a drug that could then be used to expand the approved indication and satisfy the requirements of a European health authority for reimbursement?
Smith & Nephew Plc of the UK has moved to strengthen its position in wound care with the acquisition for $782 million in cash of most of the assets of privately-held Healthpoint Biotherapeutics of Fort Worth, Texas, US. The acquisition was announced on 28 November 2012.
Sanofi SA has entered a collaboration with Selecta Biosciences Inc in the US to develop immunotherapies for up to three different allergies.
MorphoSys AG has negotiated rights to exclusively license new peptide technology from privately-owned Lanthio Pharma BV in the Netherlands. MorphoSys will also make an equity investment in Lanthio as part of a Series A round. Figures weren’t disclosed.
TxCell SA of France, which is developing cell-based immunotherapies for chronic inflammatory diseases, has raised €12.4 million from existing shareholders and a new investor to finance a proof-of-concept study of its lead product for Crohn’s disease.